MedPage Today June 24, 2024
— Phase II data support testing pemvidutide for comorbid obesity and liver conditions
ORLANDO — Novel dual GLP-1 and glucagon agonist pemvidutide reduced weight and lipids with somewhat less muscle loss than expected, the phase II MOMENTUM trial showed.
Weight lost over 48 weeks ranged in a dose-dependent manner from 10.3% with the 1.2 mg weekly dose to 15.6% with the 2.4 mg weekly dose (P<0.001 vs placebo for all), reported Louis Aronne, MD, of Weill Cornell Medicine in New York City.
And the mean 32.2 lb shed likely wasn’t the plateau level, as trajectory curves continued downward at the 48 week mark, he said at the American Diabetes Association (ADA) annual meeting.
Pemvidutide reduced LDL cholesterol by 6.2% to...
Today's Sponsors
Today's Sponsor